{"disease":{"id":"biochemically-recurrent-prostate-cancer","name":"biochemically recurrent prostate cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05794906","title":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":985,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05526248","title":"A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Bayer","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}